Journal
JOURNAL OF AFFECTIVE DISORDERS
Volume 132, Issue 3, Pages 396-400Publisher
ELSEVIER
DOI: 10.1016/j.jad.2011.03.011
Keywords
Hamilton depression scale; Inventory of Depressive Symptomatology; Principal component analysis; Item response theory analysis
Categories
Funding
- Astra-Zeneca
- Lilly
- H Lundbeck A/S
- Organon
- Abbott Laboratories
- Alkermes, Inc.
- Aspect Medical Systems
- AstraZeneca
- BioResearch
- BrainCells Inc.
- Bristol-Myers Squibb
- Cephalon, Inc.
- Clinical Trials Solutions, LLC
- Covidien
- Eli Lilly and Company
- En Vivo Pharmaceuticals, Inc.
- Forest Pharmaceuticals, Inc.
- Ganeden Biotech, Inc.
- GlaxoSmithKline
- Johnson & Johnson Pharmaceutical Research Development
- Lichtwer Pharma GmbH
- Lorex Pharmaceuticals
- Novartis AG
- Organon Pharmaceuticals
- PamLab, LLC.
- Pfizer Inc.
- Pharmavite(R) LLC
- Roche
- RTC Logic, LLC
- Sanofi-Aventis US LLC
- Shire
- Solvay Pharmaceuticals, Inc.
- Solvay Pharmaceuticals, Inc.
- Synthelabo
- Wyeth-Ayerst Laboratories
- Agency for Healthcare Research and Quality (AHRQ)
- Corcept Therapeutics, Inc.
- Cyberonics, Inc.
- Merck
- National Alliance for Research in Schizophrenia and Depression
- National Institute of Mental Health
- National Institute on Drug Abuse
- Novartis
- Pharmacia Upjohn
- Predix Pharmaceuticals (Epix)
- Targacept
- Abbott Laboratories, Inc.
- Abdi Ibrahim
- Akzo (Organon Pharmaceuticals Inc.)
- Bristol-Myers Squibb Company
- Evotec
- Fabre Kramer Pharmaceuticals, Inc.
- Forest Pharmaceuticals
- Janssen Pharmaceutica Products
- LP
- Johnson Johnson PRD
- Eli Lilly Company
- Meade Johnson
- Medtronic
- Neuronetics
- Otsuka Pharmaceuticals
- Parke-Davis Pharmaceuticals, Inc.
- Sepracor
- SHIRE Development
- VantagePoint
- National Alliance for Research on Schizophrenia and Depression (NARSAD)
- National Institutes of Health
Ask authors/readers for more resources
Background: The factor structure and dimensionality of the HAM-D-17 and the IDS-C-30 are as yet uncertain, because psychometric analyses of these scales have been performed without a clear separation between factor structure profile and dimensionality (total scores being a sufficient statistic). Methods: The first treatment step (Level 1) in the STAR*D study provided a dataset of 4041 outpatients with DSM-IV nonpsychotic major depression. The HAM-D-17 and IDS-C-30 were evaluated by principal component analysis (PCA) without rotation. Mokken analysis tested the unidimensionality of the IDS-C-6, which corresponds to the unidimensional HAM-D-6. Results: For both the HAM-D-17 and IDS-C-30, PCA identified a bi-directional factor contrasting the depressive symptoms versus the neurovegetative symptoms. The HAM-D-6 and the corresponding IDS-C-6 symptoms all emerged in the depression factor. Both the HAM-D-6 and IDS-C-6 were found to be unidimensional scales, i.e., their total scores are each a sufficient statistic for the measurement of depressive states. Limitations: STAR*D used only one medication in Level 1. Conclusions: The unidimensional HAM-D-6 and IDS-C-6 should be used when evaluating the pure clinical effect of antidepressive treatment, whereas the multidimensional HAM-D-17 and IDS-C-30 should be considered when selecting antidepressant treatment. (C) 2011 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available